Teva Launches Honestly HD Website to Provide People Living With Huntington’s Disease (HD) Information, Inspiration and Resources on HD Chorea

New website and Twitter channel aim to help the HD community understand what to expect with HD chorea and how to talk to a healthcare provider about preserving independence for as long as possible

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of the Honestly HD website, which aims to provide information, inspiration and resources to help people understand what to expect with Huntington’s Disease (HD) chorea – one of the most visible and treatable symptoms of HD – and, how to talk to their doctor about preserving independence. In addition to the newly launched site, a Twitter channel, @HonestlyHD, has launched to further support the HD community and expand the resources already available through the Honestly HD Facebook community, which provides a virtual space for sharing personal stories and resources.¹

HD is an inherited disorder in which nerve cells in the brain break down and are irreversibly damaged.^2,3 Ninety percent of people with HD will develop chorea, a movement disorder in which abnormally high levels of dopamine in the brain cause involuntary body movements such as fidgeting, squirming, or jerking that can affect the hands and face, limbs and torso or speech and mobility.^1,4 While it’s not the only symptom of HD, chorea can have a significant impact on daily activities and progressively limit peoples’ lives.

“There is an immense amount to know about HD, which can lead to feeling overwhelmed and confused. While there is no cure for HD, many symptoms can be managed, helping to ease some of the challenges of living with the disease. Early treatment of chorea, for example, can help you stay independent longer,”² said Dr. Victor W. Sung, Chair of HDSA’s National Board of Trustees, Director of HDSA Center of Excellence, Alabama. “Honestly HD provides patients and families affected by HD a central place to access helpful information and resources, as well as hear about the experiences of others to feel a sense of community.”

In addition to providing information about HD and chorea, HonestlyHD.com features helpful resources, including steps to help people decide how and when to address HD chorea, a HD chorea discussion guide to help patients and their care partners prepare for doctor’s appointments, and stories from patients and care partners about their experiences.

“The progressive nature of HD can create feelings of isolation for patients and their families, and makes planning ahead crucial,” said Michelle Roberts, MBA, MSN, NP, Senior Director, Medical Patient Advocacy, Teva Pharmaceuticals.¹ “Our hope is that in addition to providing information and resources to aid in managing HD chorea symptoms and planning for the future, Honestly HD fosters a supportive and inspiring community so patients and their families don’t feel alone. Honestly HD underscores our commitment to supporting patients as they face the many complex challenges of living with a degenerative disease, and hopefully provides them with some actionable steps they can take to potentially reduce disease burden.”

To learn more, please visit HonestlyHD.com or @HonestlyHD or join the community at Honestly HD.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to; our ability to successfully compete in the marketplace, including our ability to develop and commercialize biopharmaceutical products, competition for our specialty products, including AUSTEDO^®, AJOVY^® and COPAXONE^®; our ability to achieve expected results from investments in our product pipeline, our ability to develop and commercialize additional pharmaceutical products, and the effectiveness of our patents and other measures to protect our intellectual property rights; our substantial indebtedness; our business and operations in general, including uncertainty regarding the COVID-19 pandemic and the governmental and societal responses thereto; our ability to successfully execute and maintain the activities and efforts related to the measures we have taken or may take in response to the COVID-19 pandemic and associated costs therewith; costs and delays resulting from the extensive pharmaceutical regulation to which we are subject or delays in governmental processing time due to travel and work restrictions caused by the COVID-19 pandemic; compliance, regulatory and litigation matters, including failure to comply with complex legal and regulatory environments; other financial and economic risks; and other factors discussed in our Quarterly Report on Form 10-Q for the second quarter of 2022 and in our Annual Report on Form 10-K for the year ended December 31, 2021, including in the section captioned “Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

¹ Claassen DO, DeCourcy J, Mellor J, Johnston C, Iyer RG. Impact of chorea on self-care activity, employment, and health-care resource use in patients with Huntington's disease. JHEOR. 2021;8(1):99-105. doi:10.36469/jheor.2021.24620.

² Huntington’s disease information page. National Institute of Neurological Disorders and Stroke. Accessed September 16, 2022. https://www.ninds.nih.gov/Disorders/All-Disorders/Huntingtons-Disease-Information-Page 2.

³ Nance M, Paulsen JS, Rosenblatt A, Wheelock V. A Physician’s Guide to the Management of Huntington’s Disease. 3rd ed. New York, NY: Huntington’s Disease Society of America; 2011. Accessed September 16, 2022. https://hdsa.org/wp-content/uploads/2015/03/PhysiciansGuide_3rd-Edition.pdf.

⁴ Cepeda C, Murphy K, Parent M, Levine MS. The role of dopamine in Huntington’s disease. Prog Brain Res. 2014;211:235-254. Doi:10.1016/B978-0-444-63425-2.00010-6.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220926005087/en/